Patents by Inventor Torben Østerlund

Torben Østerlund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20210363213
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 11111285
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 10406207
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 10, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS
    Publication number: 20190270789
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 5, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20190135886
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 9, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 10131702
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 20, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 10100097
    Abstract: The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: October 16, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9861706
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20170281709
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 5, 2017
    Inventors: Trine Skovlund Ryge NEERUP, Torben ØSTERLUND, Jakob Lind TOLBORG, Keld FOSGERAU, Ulrika MARTENSSON, Marianne BRORSON, Kamilla ROLSTED
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9649362
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 16, 2017
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20160184400
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: June 10, 2015
    Publication date: June 30, 2016
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES
    Publication number: 20160082118
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 24, 2016
    Inventors: Jakob Lind TOLBORG, Trine Skovlund Ryge NEERUP, Keld FOSGERAU, Torben ØSTERLUND, Dorthe Lennert Christensen ALMHOLT, Lone Frost LARSEN
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9259477
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: February 16, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20150299281
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: May 3, 2013
    Publication date: October 22, 2015
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9089538
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 28, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES
    Publication number: 20140336107
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: November 2, 2012
    Publication date: November 13, 2014
    Inventors: Jakob Lind Tolborg, Trine Neerup, Keid Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20130143793
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 6, 2013
    Applicant: ZEALAND PHARMA A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted